In recent years, the review and approval of rare disease drugs in China has been accelerated, and the negotiation of access to the national medical insurance drug catalogue has been fully launched. Through comparative analysis of the national conversation catalogue over the years, it can be seen that from 2017 to 2022, the number of rare disease drugs included in medical insurance through national negotiations has increased from zero to 29 year by year, the time from listing to inclusion in medical insurance has been significantly shortened, and the accessibility has been significantly improved. The list of rare diseases drugs covered 16 rare disease, including 26 (89.6%) imported enterprise products and 3 (10.4%) domestic enterprise products. It reveals that although the number of rare disease drugs listed and medical insurance coverage in China have increased, the coverage of rare diseases is still small, and the research and innovation ability of domestic pharmaceutical enterprises is relatively weak. It is suggested that medical insurance, medical treatment and medicine should continue to play a synergistic role to provide sustainable impetus for the guarantee of rare disease drug use in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |